Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (544)	7/30/1998 3:21:00 PM
From: Debbie Lee-Cassimus	Read Replies (1) \| Respond to of 961

RESEARCH ALERT - Gilead Sciences <GILD.O> upgraded CHICAGO, July 28 (Reuters) - Vector Securities analyst Michael King said he raised his rating on Gilead Sciences Inc. to buy from attractive. Gilead shares are off nearly 40 percent from level at which they were trading prior to 12th World AIDS Conference in late June. "While fundamentals have recently slipped for Gilead, especially as regards the prospects for both PREVEON for HIV infection and GS 4104 for the treatment of influenza, it is our opinion that the share price decline has more than accounted for these factors," said King. Despite downward revisions in earnings per share, King said he continues to like Gilead's long-term prospects and considers it be one of "our top two to three year stock selections" with a price target of $33. Stock down 5/16 to 22-11/16. 20:16 07-28-98